Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention
BackgroundsDiabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has important c...
Gespeichert in:
| Veröffentlicht in: | BMC nephrology 2021-06, Vol.22 (1), p.206-206, Article 206 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 206 |
|---|---|
| container_issue | 1 |
| container_start_page | 206 |
| container_title | BMC nephrology |
| container_volume | 22 |
| creator | Zhang, H. Fu, H. Fu, X. Zhang, J. Zhang, P. Yang, S. Zeng, Z. Fu, N. Guo, Z. |
| description | BackgroundsDiabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has important clinical significance for evaluating blood glucose control in diabetic patients in the past 3 months. This study aimed to assess whether preoperative HbA1c levels in diabetic patients who received CAG/PCI impacted the occurrence of postoperative CIN.MethodsWe reviewed the incidence of preoperative HbA1c and postoperative CIN in 670 patients with CAG/PCI from January 1, 2020 to October 30, 2020 and divided the preoperative HbA1c levels into 5 groups. Blood samples were collected at admission, 48h and 72h after operation to measure the Scr value of patients. Categorical variables were compared using a chi-square test, and continuous variables were compared using an analysis of variance. Fisher's exact test was used to compare the percentages when the expected frequency was less than 5. Univariable and multivariable logistic regression analysis was used to exclude the influence of confounding factors, and P for trend was used to analyze the trend between HbA1c levels and the increased risk of CIN.ResultsPatients with elevated HbA1c had higher BMI, FBG, and LDL-C, and they were more often on therapy with hypoglycemic agents, Insulin and PCI. They also had higher basal, 48h and 72h Scr. The incidence of CIN in the 5 groups of patients were: 9.8, 11.9, 15.2, 25.3, 48.1%. (p9.5%, the incidence of CIN trends increase. Therefore, we should attach great importance to patients with elevated HbA1c at admission and take more active measures to prevent CIN. |
| doi_str_mv | 10.1186/s12882-021-02405-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_webof</sourceid><recordid>TN_cdi_webofscience_primary_000660617800002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A665461655</galeid><doaj_id>oai_doaj_org_article_43cf81e77ed94f4f96db33d6ea97ae7f</doaj_id><sourcerecordid>A665461655</sourcerecordid><originalsourceid>FETCH-LOGICAL-c629t-86c4c6f0e22a5a02b3b2a9ff58b860d067ae7fb3a1fddecedf4a115e6d92d1ae3</originalsourceid><addsrcrecordid>eNqNUk1v1DAQjRCIlsIf4IAicUFCaf2ROMkFqVpBqVSJC5wtxx5nXbL2YjuL8of4ncx2Sz8QBxRZsSbvvZl5eUXxmpJTSjtxlijrOlYRRvHUpKmWJ8UxrVtaMS76pw_uR8WLlK4JoW1Xk-fFEa9J23HCj4tfF9OiQ1omlcGUa9iEcQqD8-UEO5hSqbwp8xrK6NL30oZY6uBzVClXzptZI8fDdh3DVuX1UiLPODVAdrrEigOfUzl7A3EMzo9IjsGruJQqZogujFFt18vZFqKes_IQ5nSPcR4xO5Rwwb8snlk1JXh1-z4pvn36-HX1ubr6cnG5Or-qtGB9rjqhay0sAcZUowgb-MBUb23TDZ0ghohWQWsHrqg1BnB6WytKGxCmZ4Yq4CfF5UHXBHUtt9FtcBIZlJM3hRBHiaM7PYGsubYdhbYF09e2tr0wA-dGgOpvuqDWh4PWdh42YDTsjZseiT7-4t1ajmEnO9ryljco8O5WIIYfM6QsNy5pmKaDU5I1XHSEkJ4h9O1f0OswR49WIarmdS94Q-9Ro8IFnLcB--q9qDwXoqkFFc2-7ek_UPgY2Dj8_WAd1h8R2IGgY0gpgr3bkRK5T6o8JFViUuVNUuWCpDcP3bmj_IkmAt4fAD9hCDZpDJOGOxiuLQQRGGi8kb0B3f-jVy6rfapWYfaZ_wbuAwvy</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2543496351</pqid></control><display><type>article</type><title>Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerNature Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>Zhang, H. ; Fu, H. ; Fu, X. ; Zhang, J. ; Zhang, P. ; Yang, S. ; Zeng, Z. ; Fu, N. ; Guo, Z.</creator><creatorcontrib>Zhang, H. ; Fu, H. ; Fu, X. ; Zhang, J. ; Zhang, P. ; Yang, S. ; Zeng, Z. ; Fu, N. ; Guo, Z.</creatorcontrib><description>BackgroundsDiabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has important clinical significance for evaluating blood glucose control in diabetic patients in the past 3 months. This study aimed to assess whether preoperative HbA1c levels in diabetic patients who received CAG/PCI impacted the occurrence of postoperative CIN.MethodsWe reviewed the incidence of preoperative HbA1c and postoperative CIN in 670 patients with CAG/PCI from January 1, 2020 to October 30, 2020 and divided the preoperative HbA1c levels into 5 groups. Blood samples were collected at admission, 48h and 72h after operation to measure the Scr value of patients. Categorical variables were compared using a chi-square test, and continuous variables were compared using an analysis of variance. Fisher's exact test was used to compare the percentages when the expected frequency was less than 5. Univariable and multivariable logistic regression analysis was used to exclude the influence of confounding factors, and P for trend was used to analyze the trend between HbA1c levels and the increased risk of CIN.ResultsPatients with elevated HbA1c had higher BMI, FBG, and LDL-C, and they were more often on therapy with hypoglycemic agents, Insulin and PCI. They also had higher basal, 48h and 72h Scr. The incidence of CIN in the 5 groups of patients were: 9.8, 11.9, 15.2, 25.3, 48.1%. (p<0.0001) The multivariate analysis confirmed that in the main high-risk subgroup, patients with elevated HbA1C levels (<greater than or equal to>8.8%) had a higher risk of CIN disease. Trend test showed the change of OR (1.000,1.248,1.553,2.625,5.829).ConclusionsStudies have shown that in diabetic patients undergoing CAG/PCI, elevated HbA1c is independently associated with the risk of CIN, and when HbA1c>9.5%, the incidence of CIN trends increase. Therefore, we should attach great importance to patients with elevated HbA1c at admission and take more active measures to prevent CIN.</description><identifier>ISSN: 1471-2369</identifier><identifier>EISSN: 1471-2369</identifier><identifier>DOI: 10.1186/s12882-021-02405-y</identifier><identifier>PMID: 34078303</identifier><language>eng</language><publisher>LONDON: Springer Nature</publisher><subject>Aged ; Angiography ; Angioplasty ; Arteriography ; Blood glucose ; Blood pressure ; Care and treatment ; Complications ; Complications and side effects ; Contrast agents ; Contrast media ; Contrast Media - adverse effects ; Contrast-induced nephropathy ; Coronary Angiography ; Coronary Disease - complications ; Coronary Disease - diagnostic imaging ; Coronary Disease - therapy ; Coronary vessels ; Creatinine ; Diabetes ; Diabetes mellitus ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetics ; Female ; Glucose ; Glycated Hemoglobin A - analysis ; Glycosylated hemoglobin ; Health aspects ; Heart failure ; Hemoglobin ; Hospitalization ; Humans ; Hydration ; Hyperglycemia ; Hypoglycemic agents ; Hypotension ; Insulin ; Kidney diseases ; Kidney Diseases - chemically induced ; Life Sciences & Biomedicine ; Low density lipoprotein ; Male ; Measurement ; Middle Aged ; Multivariate analysis ; Nephrology ; Nephropathy ; Patients ; Percutaneous Coronary Intervention ; Regression analysis ; Risk Factors ; Risk groups ; Science & Technology ; Surgery ; Transluminal angioplasty ; Trinucleotide repeats ; Urology & Nephrology ; Variables ; Veins & arteries</subject><ispartof>BMC nephrology, 2021-06, Vol.22 (1), p.206-206, Article 206</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000660617800002</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c629t-86c4c6f0e22a5a02b3b2a9ff58b860d067ae7fb3a1fddecedf4a115e6d92d1ae3</citedby><cites>FETCH-LOGICAL-c629t-86c4c6f0e22a5a02b3b2a9ff58b860d067ae7fb3a1fddecedf4a115e6d92d1ae3</cites><orcidid>0000-0002-4639-3810</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173735/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173735/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2106,2118,27933,27934,39267,53800,53802</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34078303$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, H.</creatorcontrib><creatorcontrib>Fu, H.</creatorcontrib><creatorcontrib>Fu, X.</creatorcontrib><creatorcontrib>Zhang, J.</creatorcontrib><creatorcontrib>Zhang, P.</creatorcontrib><creatorcontrib>Yang, S.</creatorcontrib><creatorcontrib>Zeng, Z.</creatorcontrib><creatorcontrib>Fu, N.</creatorcontrib><creatorcontrib>Guo, Z.</creatorcontrib><title>Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention</title><title>BMC nephrology</title><addtitle>BMC NEPHROL</addtitle><addtitle>BMC Nephrol</addtitle><description>BackgroundsDiabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has important clinical significance for evaluating blood glucose control in diabetic patients in the past 3 months. This study aimed to assess whether preoperative HbA1c levels in diabetic patients who received CAG/PCI impacted the occurrence of postoperative CIN.MethodsWe reviewed the incidence of preoperative HbA1c and postoperative CIN in 670 patients with CAG/PCI from January 1, 2020 to October 30, 2020 and divided the preoperative HbA1c levels into 5 groups. Blood samples were collected at admission, 48h and 72h after operation to measure the Scr value of patients. Categorical variables were compared using a chi-square test, and continuous variables were compared using an analysis of variance. Fisher's exact test was used to compare the percentages when the expected frequency was less than 5. Univariable and multivariable logistic regression analysis was used to exclude the influence of confounding factors, and P for trend was used to analyze the trend between HbA1c levels and the increased risk of CIN.ResultsPatients with elevated HbA1c had higher BMI, FBG, and LDL-C, and they were more often on therapy with hypoglycemic agents, Insulin and PCI. They also had higher basal, 48h and 72h Scr. The incidence of CIN in the 5 groups of patients were: 9.8, 11.9, 15.2, 25.3, 48.1%. (p<0.0001) The multivariate analysis confirmed that in the main high-risk subgroup, patients with elevated HbA1C levels (<greater than or equal to>8.8%) had a higher risk of CIN disease. Trend test showed the change of OR (1.000,1.248,1.553,2.625,5.829).ConclusionsStudies have shown that in diabetic patients undergoing CAG/PCI, elevated HbA1c is independently associated with the risk of CIN, and when HbA1c>9.5%, the incidence of CIN trends increase. Therefore, we should attach great importance to patients with elevated HbA1c at admission and take more active measures to prevent CIN.</description><subject>Aged</subject><subject>Angiography</subject><subject>Angioplasty</subject><subject>Arteriography</subject><subject>Blood glucose</subject><subject>Blood pressure</subject><subject>Care and treatment</subject><subject>Complications</subject><subject>Complications and side effects</subject><subject>Contrast agents</subject><subject>Contrast media</subject><subject>Contrast Media - adverse effects</subject><subject>Contrast-induced nephropathy</subject><subject>Coronary Angiography</subject><subject>Coronary Disease - complications</subject><subject>Coronary Disease - diagnostic imaging</subject><subject>Coronary Disease - therapy</subject><subject>Coronary vessels</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetics</subject><subject>Female</subject><subject>Glucose</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Glycosylated hemoglobin</subject><subject>Health aspects</subject><subject>Heart failure</subject><subject>Hemoglobin</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Hydration</subject><subject>Hyperglycemia</subject><subject>Hypoglycemic agents</subject><subject>Hypotension</subject><subject>Insulin</subject><subject>Kidney diseases</subject><subject>Kidney Diseases - chemically induced</subject><subject>Life Sciences & Biomedicine</subject><subject>Low density lipoprotein</subject><subject>Male</subject><subject>Measurement</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Nephrology</subject><subject>Nephropathy</subject><subject>Patients</subject><subject>Percutaneous Coronary Intervention</subject><subject>Regression analysis</subject><subject>Risk Factors</subject><subject>Risk groups</subject><subject>Science & Technology</subject><subject>Surgery</subject><subject>Transluminal angioplasty</subject><subject>Trinucleotide repeats</subject><subject>Urology & Nephrology</subject><subject>Variables</subject><subject>Veins & arteries</subject><issn>1471-2369</issn><issn>1471-2369</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNqNUk1v1DAQjRCIlsIf4IAicUFCaf2ROMkFqVpBqVSJC5wtxx5nXbL2YjuL8of4ncx2Sz8QBxRZsSbvvZl5eUXxmpJTSjtxlijrOlYRRvHUpKmWJ8UxrVtaMS76pw_uR8WLlK4JoW1Xk-fFEa9J23HCj4tfF9OiQ1omlcGUa9iEcQqD8-UEO5hSqbwp8xrK6NL30oZY6uBzVClXzptZI8fDdh3DVuX1UiLPODVAdrrEigOfUzl7A3EMzo9IjsGruJQqZogujFFt18vZFqKes_IQ5nSPcR4xO5Rwwb8snlk1JXh1-z4pvn36-HX1ubr6cnG5Or-qtGB9rjqhay0sAcZUowgb-MBUb23TDZ0ghohWQWsHrqg1BnB6WytKGxCmZ4Yq4CfF5UHXBHUtt9FtcBIZlJM3hRBHiaM7PYGsubYdhbYF09e2tr0wA-dGgOpvuqDWh4PWdh42YDTsjZseiT7-4t1ajmEnO9ryljco8O5WIIYfM6QsNy5pmKaDU5I1XHSEkJ4h9O1f0OswR49WIarmdS94Q-9Ro8IFnLcB--q9qDwXoqkFFc2-7ek_UPgY2Dj8_WAd1h8R2IGgY0gpgr3bkRK5T6o8JFViUuVNUuWCpDcP3bmj_IkmAt4fAD9hCDZpDJOGOxiuLQQRGGi8kb0B3f-jVy6rfapWYfaZ_wbuAwvy</recordid><startdate>20210602</startdate><enddate>20210602</enddate><creator>Zhang, H.</creator><creator>Fu, H.</creator><creator>Fu, X.</creator><creator>Zhang, J.</creator><creator>Zhang, P.</creator><creator>Yang, S.</creator><creator>Zeng, Z.</creator><creator>Fu, N.</creator><creator>Guo, Z.</creator><general>Springer Nature</general><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4639-3810</orcidid></search><sort><creationdate>20210602</creationdate><title>Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention</title><author>Zhang, H. ; Fu, H. ; Fu, X. ; Zhang, J. ; Zhang, P. ; Yang, S. ; Zeng, Z. ; Fu, N. ; Guo, Z.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c629t-86c4c6f0e22a5a02b3b2a9ff58b860d067ae7fb3a1fddecedf4a115e6d92d1ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Angiography</topic><topic>Angioplasty</topic><topic>Arteriography</topic><topic>Blood glucose</topic><topic>Blood pressure</topic><topic>Care and treatment</topic><topic>Complications</topic><topic>Complications and side effects</topic><topic>Contrast agents</topic><topic>Contrast media</topic><topic>Contrast Media - adverse effects</topic><topic>Contrast-induced nephropathy</topic><topic>Coronary Angiography</topic><topic>Coronary Disease - complications</topic><topic>Coronary Disease - diagnostic imaging</topic><topic>Coronary Disease - therapy</topic><topic>Coronary vessels</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetics</topic><topic>Female</topic><topic>Glucose</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Glycosylated hemoglobin</topic><topic>Health aspects</topic><topic>Heart failure</topic><topic>Hemoglobin</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Hydration</topic><topic>Hyperglycemia</topic><topic>Hypoglycemic agents</topic><topic>Hypotension</topic><topic>Insulin</topic><topic>Kidney diseases</topic><topic>Kidney Diseases - chemically induced</topic><topic>Life Sciences & Biomedicine</topic><topic>Low density lipoprotein</topic><topic>Male</topic><topic>Measurement</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Nephrology</topic><topic>Nephropathy</topic><topic>Patients</topic><topic>Percutaneous Coronary Intervention</topic><topic>Regression analysis</topic><topic>Risk Factors</topic><topic>Risk groups</topic><topic>Science & Technology</topic><topic>Surgery</topic><topic>Transluminal angioplasty</topic><topic>Trinucleotide repeats</topic><topic>Urology & Nephrology</topic><topic>Variables</topic><topic>Veins & arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, H.</creatorcontrib><creatorcontrib>Fu, H.</creatorcontrib><creatorcontrib>Fu, X.</creatorcontrib><creatorcontrib>Zhang, J.</creatorcontrib><creatorcontrib>Zhang, P.</creatorcontrib><creatorcontrib>Yang, S.</creatorcontrib><creatorcontrib>Zeng, Z.</creatorcontrib><creatorcontrib>Fu, N.</creatorcontrib><creatorcontrib>Guo, Z.</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, H.</au><au>Fu, H.</au><au>Fu, X.</au><au>Zhang, J.</au><au>Zhang, P.</au><au>Yang, S.</au><au>Zeng, Z.</au><au>Fu, N.</au><au>Guo, Z.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention</atitle><jtitle>BMC nephrology</jtitle><stitle>BMC NEPHROL</stitle><addtitle>BMC Nephrol</addtitle><date>2021-06-02</date><risdate>2021</risdate><volume>22</volume><issue>1</issue><spage>206</spage><epage>206</epage><pages>206-206</pages><artnum>206</artnum><issn>1471-2369</issn><eissn>1471-2369</eissn><abstract>BackgroundsDiabetes mellitus is an independent risk factor for Contrast-induced nephropathy (CIN) in patients undergoing Coronary arteriography (CAG)/percutaneous coronary intervention (PCI). Glycosylated hemoglobin (HbA1c) is the gold standard to measure blood glucose control, which has important clinical significance for evaluating blood glucose control in diabetic patients in the past 3 months. This study aimed to assess whether preoperative HbA1c levels in diabetic patients who received CAG/PCI impacted the occurrence of postoperative CIN.MethodsWe reviewed the incidence of preoperative HbA1c and postoperative CIN in 670 patients with CAG/PCI from January 1, 2020 to October 30, 2020 and divided the preoperative HbA1c levels into 5 groups. Blood samples were collected at admission, 48h and 72h after operation to measure the Scr value of patients. Categorical variables were compared using a chi-square test, and continuous variables were compared using an analysis of variance. Fisher's exact test was used to compare the percentages when the expected frequency was less than 5. Univariable and multivariable logistic regression analysis was used to exclude the influence of confounding factors, and P for trend was used to analyze the trend between HbA1c levels and the increased risk of CIN.ResultsPatients with elevated HbA1c had higher BMI, FBG, and LDL-C, and they were more often on therapy with hypoglycemic agents, Insulin and PCI. They also had higher basal, 48h and 72h Scr. The incidence of CIN in the 5 groups of patients were: 9.8, 11.9, 15.2, 25.3, 48.1%. (p<0.0001) The multivariate analysis confirmed that in the main high-risk subgroup, patients with elevated HbA1C levels (<greater than or equal to>8.8%) had a higher risk of CIN disease. Trend test showed the change of OR (1.000,1.248,1.553,2.625,5.829).ConclusionsStudies have shown that in diabetic patients undergoing CAG/PCI, elevated HbA1c is independently associated with the risk of CIN, and when HbA1c>9.5%, the incidence of CIN trends increase. Therefore, we should attach great importance to patients with elevated HbA1c at admission and take more active measures to prevent CIN.</abstract><cop>LONDON</cop><pub>Springer Nature</pub><pmid>34078303</pmid><doi>10.1186/s12882-021-02405-y</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4639-3810</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2369 |
| ispartof | BMC nephrology, 2021-06, Vol.22 (1), p.206-206, Article 206 |
| issn | 1471-2369 1471-2369 |
| language | eng |
| recordid | cdi_webofscience_primary_000660617800002 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerNature Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; EZB-FREE-00999 freely available EZB journals; PubMed Central; Springer Nature OA/Free Journals |
| subjects | Aged Angiography Angioplasty Arteriography Blood glucose Blood pressure Care and treatment Complications Complications and side effects Contrast agents Contrast media Contrast Media - adverse effects Contrast-induced nephropathy Coronary Angiography Coronary Disease - complications Coronary Disease - diagnostic imaging Coronary Disease - therapy Coronary vessels Creatinine Diabetes Diabetes mellitus Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - complications Diabetics Female Glucose Glycated Hemoglobin A - analysis Glycosylated hemoglobin Health aspects Heart failure Hemoglobin Hospitalization Humans Hydration Hyperglycemia Hypoglycemic agents Hypotension Insulin Kidney diseases Kidney Diseases - chemically induced Life Sciences & Biomedicine Low density lipoprotein Male Measurement Middle Aged Multivariate analysis Nephrology Nephropathy Patients Percutaneous Coronary Intervention Regression analysis Risk Factors Risk groups Science & Technology Surgery Transluminal angioplasty Trinucleotide repeats Urology & Nephrology Variables Veins & arteries |
| title | Glycosylated hemoglobin levels and the risk for contrast-induced nephropathy in diabetic patients undergoing coronary arteriography/percutaneous coronary intervention |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T11%3A08%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glycosylated%20hemoglobin%20levels%20and%20the%20risk%20for%20contrast-induced%20nephropathy%20in%20diabetic%20patients%20undergoing%20coronary%20arteriography/percutaneous%20coronary%20intervention&rft.jtitle=BMC%20nephrology&rft.au=Zhang,%20H.&rft.date=2021-06-02&rft.volume=22&rft.issue=1&rft.spage=206&rft.epage=206&rft.pages=206-206&rft.artnum=206&rft.issn=1471-2369&rft.eissn=1471-2369&rft_id=info:doi/10.1186/s12882-021-02405-y&rft_dat=%3Cgale_webof%3EA665461655%3C/gale_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2543496351&rft_id=info:pmid/34078303&rft_galeid=A665461655&rft_doaj_id=oai_doaj_org_article_43cf81e77ed94f4f96db33d6ea97ae7f&rfr_iscdi=true |